Timothy A. Springer, Director, 10% Owner at Cartesian Therapeutics, Inc. (RNAC), bought 680,441 shares at $20.18 ($7.5M) on 2024-10-03, disclosed to the SEC on 2024-10-04.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 317,879 | $0 | 0.0% |
| 2 | $17.38 | 5,514 | $96K | 1.3% |
| 3 | $17.38 | 5,514 | $96K | 1.3% |
| 4 | $18.25 | 29,847 | $545K | 7.3% |
| 5 | $18.25 | 29,847 | $545K | 7.3% |
| 6 | $19.01 | 10,249 |
| $195K |
| 2.6% |
| 7 | $19.01 | 10,249 | $195K | 2.6% |
| 8 | $20.18 | 50,489 | $1.0M | 13.6% |
| 9 | $20.18 | 50,489 | $1.0M | 13.6% |
| 10 | $21.17 | 21,278 | $450K | 6.0% |
| 11 | $21.17 | 21,278 | $450K | 6.0% |
| 12 | $21.86 | 8,043 | $176K | 2.3% |
| 13 | $21.86 | 8,043 | $176K | 2.3% |
| 14 | $21.35 | 9,892 | $211K | 2.8% |
| 15 | $21.35 | 9,892 | $211K | 2.8% |
| 16 | $22.35 | 48,880 | $1.1M | 14.6% |
| 17 | $23.57 | 16,650 | $392K | 5.2% |
| 18 | $23.57 | 16,650 | $392K | 5.2% |
| 19 | $23.93 | 4,879 | $117K | 1.6% |
| 20 | $23.93 | 4,879 | $117K | 1.6% |
| Total | $11.01 avg | 680,441 | $7.5M | 100% |
| Filing → |
| TECX | BUY | 2025-04-09 | $17.1M | — | Filing → |
| RNAC | BUY | 2025-03-20 | $2.7M | — | Filing → |
| TECX | BUY | 2025-02-07 | $47.0M | — | Filing → |